{
  "docId": "019de511-345d-7570-a494-480f2370811c",
  "docSlug": "ec9eb0ed92f9fb3cafb36e44028c44da",
  "documentTitle": "MaxCyte | IPO Presentation Deck | 34 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7843866,
  "pageNumber": 25,
  "pageCount": 34,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "Highlights regulatory efficiency as a competitive moat.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de511-345d-7570-a494-480f2370811c/25",
  "deckHref": "/decks/019de511-345d-7570-a494-480f2370811c",
  "deckJsonHref": "/decks/019de511-345d-7570-a494-480f2370811c.json",
  "deckAnchorHref": "/decks/019de511-345d-7570-a494-480f2370811c#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.55
      },
      "kind": "list",
      "text": "LOA allows partners to instantly reference all the information in the Master File as part of their own cell therapy product submission to regulatory authorities. Information in the Master File remains confidential. File has been updated with every substantial change to EP systems",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "07b65691-6e8e-4efc-9053-f0e0eadef3e2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "list",
      "text": "Current countries: US, Canada, Japan; and UK and Austria. Discussions underway with additional regulatory authorities: Australia, Germany, Thailand and China",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af81484b-f559-4669-a303-3c1136b6ea58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Established in 2002, MaxCyte Master File/Technical Files now referenced in over 30 clinical trials",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5612a726-2a54-4019-8b77-fdbc67de9f2e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Allows MaxCyte to issue a letter of authorization (LOA) to cell therapy partners for clinical trials in US and countries listed above",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6758ef36-2bb6-465a-a844-ce92b5a15b10",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "FDA Master File Helps Customers Efficiently Navigate Path to the Clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dca8e8a-48bc-42d4-86fa-5cb559df87c7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "08bfeb68-59d8-48b9-911f-efc2df2670e5",
      "evidence": "Allows MaxCyte to issue a letter of authorization (LOA) to cell therapy partners",
      "confidence": 0.6
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}